Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
HHSN272201500003C
IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541712 |
| PSC | AN81 — AIDS RESEARCH - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $8.0M |
| Current contract value | $8.0M |
| Potential contract value / ceiling | $8.0M |
| Start date | Feb 16, 2015 |
| Current end date | Feb 15, 2020 |
| Potential end date | Feb 15, 2022 |
| Latest award activity | Sep 4, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 15 of 15 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 4, 2026 | P00014 | $-103.7K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Mar 27, 2025 | P00013 | $-49.4K | SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| May 8, 2024 | P00012 | $-50.8K | SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Aug 4, 2023 | P00011 | $100.0K | SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Dec 15, 2022 | P00010 | $0 | SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Nov 30, 2021 | P00009 | $0 | EO14042: THE PURPOSE OF THIS CONTRACT IS TO PROVIDE SMALL SCALE SYNTHESIS OF COMPOUNDS IN QUANTITIES REQUIRED FOR TESTING IN EITHER IN VITRO OR IN ANIMALS, AND LARGE SCALE SYNTHESIS OF COMPOUNDS FOR EARLY PHASE I CLINICAL STUDIES. THE CONTRACT WILL P |
| Feb 10, 2021 | P00008 | $1.3M | THE PURPOSE OF THIS CONTRACT IS TO PROVIDE SMALL SCALE SYNTHESIS OF COMPOUNDS IN QUANTITIES REQUIRED FOR TESTING IN EITHER IN VITRO OR IN ANIMALS, AND LARGE SCALE SYNTHESIS OF COMPOUNDS FOR EARLY PHASE I CLINICAL STUDIES. THE CONTRACT WILL PROVIDE RE |
| Feb 5, 2020 | P00007 | $1.2M | THE PURPOSE OF THIS CONTRACT IS TO PROVIDE SMALL SCALE SYNTHESIS OF COMPOUNDS IN QUANTITIES REQUIRED FOR TESTING IN EITHER IN VITRO OR IN ANIMALS, AND LARGE SCALE SYNTHESIS OF COMPOUNDS FOR EARLY PHASE I CLINICAL STUDIES. THE CONTRACT WILL PROVIDE RE |
| Jun 28, 2019 | P00006 | $0 | THE PURPOSE OF THIS CONTRACT IS TO PROVIDE SMALL SCALE SYNTHESIS OF COMPOUNDS IN QUANTITIES REQUIRED FOR TESTING IN EITHER IN VITRO OR IN ANIMALS, AND LARGE SCALE SYNTHESIS OF COMPOUNDS FOR EARLY PHASE I CLINICAL STUDIES. THE CONTRACT WILL PROVIDE RESOURCES FOR THE SYNTHESIS OF PROMISING COMPOUNDS FOR THE TREATMENT OF HIV, TUBERCULOSIS AND OTHER INFECTIOUS DISEASES OF RELEVANCE TO THE RESEARCH AGENDA OF NIAID. |
| Feb 4, 2019 | P00005 | $1.2M | THE PURPOSE OF THIS CONTRACT IS TO PROVIDE SMALL SCALE SYNTHESIS OF COMPOUNDS IN QUANTITIES REQUIRED FOR TESTING IN EITHER IN VITRO OR IN ANIMALS, AND LARGE SCALE SYNTHESIS OF COMPOUNDS FOR EARLY PHASE I CLINICAL STUDIES. THE CONTRACT WILL PROVIDE RESOURCES FOR THE SYNTHESIS OF PROMISING COMPOUNDS FOR THE TREATMENT OF HIV, TUBERCULOSIS AND OTHER INFECTIOUS DISEASES OF RELEVANCE TO THE RESEARCH AGENDA OF NIAID. |
| Feb 13, 2018 | 4 | $1.2M | IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Jan 16, 2018 | 3 | $0 | IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Feb 1, 2017 | 2 | $1.1M | IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Feb 12, 2016 | 1 | $1.1M | IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
| Feb 12, 2015 | 0 | $1.1M | IGF::OT::IGF - SYNTHESIS OF THERAPEUTIC AGENTS FOR TREATMENT OF INFECTIOUS DISEASES |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.